Lupin gets preliminary nod for generic HIV drug Lexiva in US
Lupin said Lexiva had US sales of $71.6 million in the year ended March
- Mega bank mergers and the future of reforms
- US shale will continue to steal market share until late-2020s: Opec
- Govt starts consultation with states for mergers of regional rural banks
- No concern on liquidity of NBFCs: SBI chairman Rajnish Kumar
- Infosys, TCS, 3 other IT firms shortlisted to implement RBI’s CIMS
Hyderabad: m Lupin Ltd, India’s third largest drug maker on Wednesday said its US unit Lupin Pharmaceuticals Inc. has received preliminary approval from the US drug regulator to market a generic equivalent of GlaxoSmithKline Plc’s ViiV Healthcare’s (ViiV) antiretroviral (ARV) Lexiva tablets in 700 milligram dosage form.
Lexiva generically called fosamprenavir calcium tablets is used with other antiretroviral agents for the treatment of HIV-1 infection.
Lupin said Lexiva had US sales of $71.6 million in the year ended March, citing US-based healthcare information provider IMS Health.
Lupin is locked in a patent litigation with ViiV Healthcare, the main patent Lexiva will expire in December, 2017 with a paediatric exclusivity that runs until June 2018.
“This product was filed from Lupin’s Goa formulations manufacturing facility,” Lupin said.
Shares of Lupin rose 1.12% to close at Rs.1718.90 on BSE, the benchmark Sensex gained 0.17% to 28,024.33 points.